Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.…
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
Polyrizon (NASDAQ: PLRZ) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 9.310 USD on 20 November 2026, up 121.0% over 52 weeks. Its 52-week range is 2.880 USD to 18.20 USD: the price is 48.8% below the high and 223.3% above the low.
Its market capitalisation is 22.61M USD.
Polyrizon reports return on equity of -15.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 16.07M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.